At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825. EudraCT Number 2005-005107-42.
Gruppo Italiano Malattie EMatologiche dell'Adulto·interventional·Posted Oct 25, 2006·Updated Jan 4, 2017
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Lymphoblastic Leukemia, Acute. Completed, enrolled 53 participants across 36 sites.
Detailed Summary
The primary objective of the trial is to estimate the activity of BMS-354825 (Dasatinib) in de novo adult Ph+ ALL patients in terms of hematological complete remission (HCR) rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoblastic Leukemia, Acute
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedOct 2006
Primary CompletionSep 2008
TodayJul 2026
First PostedOct 25, 2006
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.7 years ago
Interventions
Dasatinibdrug